A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

Running, not enrolling · Phase 2

Conditions studied: X-Linked Retinitis Pigmentosa

In brief

The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.

Key facts

Study ID

NCT06646289

Run by

Janssen Research & Development, LLC

People needed

24

Starts

2024-10-10

Expected to finish

2030-10-24

Last updated by the study team

2026-07-06

Who can join

Age: 5 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Have been treated with AAV5-hRKp.RPGR in study MGT009 and have completed or is currently enrolled in Study MGT010
• Must sign an informed consent form indicating that they understand the purpose and procedures of the study and is willing to participate in the study
• Willing to adhere to the protocol and long-term follow-up

You may not qualify if…

• There are no specific exclusion criteria to enroll in this study

Where it is running

• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States
• University of Michigan Kellogg Eye Center — Ann Arbor, Michigan, United States
• Moorfields Eye Hospital — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.